Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

Open access

Abstract

Background A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV. We assessed safety and tolerability of rAAV1-PG9DP, a recombinant AAV1 vector encoding the gene for PG9, a broadly neutralising antibody against HIV. Methods This first-in-human, proof-of-concept, double-blind, phase 1, randomised, placebo-controlled, dose-escalation trial was done at one clinical research centre in the UK. Healthy men aged 18–45 years without HIV infection were randomly assigned to receive intramuscular injection with rAAV1-PG9DP or placebo in the deltoid or quadriceps in one of four dose-escalating cohorts (group A, 4 × 10 12 vector genomes; group B, 4 × 10 13 vector genomes; group C, 8 × 10 13 vector genomes; and group D, 1·2 × 10 14 vector genomes). Volunteers were followed up for 48 weeks. The primary objective was to assess safety and tolerability. A secondary objective was to assess PG9 expression in serum and related HIV neutralisation activity. All volunteers were included in primary and safety analyses. The trial is complete and is registered with ClinicalTrials.gov, number NCT01937455. Findings Between Jan 30, 2014, and Feb 28, 2017, 111 volunteers were screened for eligibility. 21 volunteers were eligible and provided consent, and all 21 completed 48 weeks of follow-up. Reactogenicity was generally mild or moderate and resolved without intervention. No probably or definitely related adverse events or serious adverse events were recorded. We detected PG9 by HIV neutralisation in the serum of four volunteers, and by RT-PCR in muscle biopsy samples from four volunteers. We did not detect PG9 by ELISA in serum. PG9 anti-drug antibody was present in ten volunteers in the higher dose groups. Both anti-AAV1 antibodies and AAV1-specific T-cell responses were detected. Interpretation Future studies should explore higher doses of AAV, alternative AAV serotypes and gene expression cassettes, or other broadly neutralising HIV antibodies. Funding International AIDS Vaccine Initiative, United States Agency for International Development, Bill & Melinda Gates Foundation, US National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3018(19)30003-7

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile
Figure 1 Trial profileCC BY · PubMed Central
Figure 2 Serum PG9 concentration, HIV neutralisation, and presence of confirmed anti-PG9 antibody Each coloured line corresponds to a different volunteer. – under HIV neutralisation indicates absence and + indicates presence of HIV neutralisation on either a nine-virus pseudovirus panel or to CAP45.2.00.G3 pseudovirus; – under PG9 anti-drug antibody indicates absence and + indicates presence of confirmed tier 2 PG9 anti-drug antibody. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.
Figure 2 Serum PG9 concentration, HIV neutralisation, and presence of confirmed anti-PG9 antibody Each coloured line corresponds to a different volunteer. – under HIV neutralisation indicates absence and + indicates presence of HIV neutralisation on either a nine-virus pseudovirus panel or to CAP45.2.00.G3 pseudovirus; – under PG9 anti-drug antibody indicates absence and + indicates presence of confirmed tier 2 PG9 anti-drug antibody. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.CC BY · PubMed Central
Figure 3 Serum AAV1 antibody titres Each coloured line corresponds to a different volunteer. BC=below cutoff. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.
Figure 3 Serum AAV1 antibody titres Each coloured line corresponds to a different volunteer. BC=below cutoff. Group A=4 × 1012 vector genomes. Group B=4 × 1013 vector genomes. Group C=8 × 1013 vector genomes. Group D and group D1=1·2 × 1014 vector genomes. LLoQ=lower limit of quantification.CC BY · PubMed Central
Figure 4 Quadriceps muscle biopsy staining (A) Sections from a placebo recipient. (B) Sections from an AAV1-PG9DP recipient from group D1.
Figure 4 Quadriceps muscle biopsy staining (A) Sections from a placebo recipient. (B) Sections from an AAV1-PG9DP recipient from group D1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 139

Metadata

Authors
Priddy, F. H., Lewis, D. J. M., Gelderblom, H. C., Hassanin, H., Streatfield, C., LaBranche, C., Hare, J., Cox, J. H., Dally, L., Bendel, D., Montefiori, D., Sayeed, E., Ackland, J., Gilmour, J., Schnepp, B. C., Wright, J. F., & Johnson, P.
Affiliations
  • International AIDS Vaccine Initiative (US)
  • Imperial College London (GB)
  • University of Surrey (GB)
  • Duke Medical Center (US)
  • Emmes (United States) (US)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Priddy, Frances H
Venue
The Lancet HIV
Publisher
Elsevier BV
Published
2019-04
Volume
6
Issue
4
Pages
e230-e239
ISSN
2352-3018 (ISSN-L)
OpenAlex
W2920817121
Cited by
131
References
31
Citations by year
2026: 13 · 2025: 17 · 2024: 21 · 2023: 20 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 7
FWCI
9.04
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet HIV (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institutes of Health during the conduct of the study (US 9408904)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
HIV prevention, adeno-associated virus vectors, gene therapy, neutralizing antibodies, vaccine safety and tolerability, anti-drug antibodies, dose escalation, healthy adults, AAV serotypes
MeSH terms
Dependovirus, Adolescent, Adult, Double-Blind Method, Follow-Up Studies, Genetic Vectors, United Kingdom, Humans, Injections, Intramuscular, Male, Middle Aged, Neutralization Tests, Placebos, Recombinant Proteins, Genetic Therapy, HIV Antibodies, HIV Infections, Young Adult, Antibodies, Neutralizing, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2352-3018(19)30003-7
The paper
Priddy, F. H., Lewis, D. J. M., Gelderblom, H. C., Hassanin, H., Streatfield, C., LaBranche, C., Hare, J., Cox, J. H., Dally, L., Bendel, D., Montefiori, D., Sayeed, E., Ackland, J., Gilmour, J., Schnepp, B. C., Wright, J. F., & Johnson, P. (2019). Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(19)30003-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.